ORG-26576

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
ORG-26576
Org 26576.svg
Identifiers
CAS Number
  • 1026791-61-6
PubChem CID
  • 13584912
ChemSpider
  • 32697513
UNII
  • 0H1IDR8Z4F
Chemical and physical data
Formula C11H12N2O2
Molar mass 204.23 g·mol−1
3D model (JSmol)
  • Interactive image

ORG-26576 is an ampakine originally developed by Cortex Pharmaceuticals and then licensed to Organon International for development. In animal studies it has been shown to effectively potentiate AMPA receptor function, leading to increased BDNF release and enhanced neuronal differentiation and survival, as well as producing nootropic effects in standardised assays.[1][2][3][4][5][6] Development as an antidepressant has been halted due to a failed Phase II trial for major depressive disorder.[7]

See also

References

  1. ^ Graeme R. Jordan; James McCulloch; Mohammed Shahid; David R. Hill; Brian Henry; Karen Horsburgh (August 2005). "Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography". Neuropharmacology. 49 (2): 254–264. doi:10.1016/j.neuropharm.2005.03.011. PMID 15993447. 
  2. ^ Xiaowei W. Su; Xiao-Yuan Li; Mounira Banasr; Ja Wook Koo; Mohammed Shahid; Brian Henry; Ronald S. Duman (October 2009). "Chronic treatment with AMPA receptor potentiator Org 26576 increases neuronal cell proliferation and survival in adult rodent hippocampus". Psychopharmacology. 206 (2): 215–222. doi:10.1007/s00213-009-1598-0. PMID 19603152. 
  3. ^ Eugene Hamlyn; Linda Brand; Mohammed Shahi; Brian H. Harvey (October 2009). "The ampakine, Org 26576, bolsters early spatial reference learning and retrieval in the Morris water maze: a subchronic, dose-ranging study in rats". Behavioural Pharmacology. 20 (7): 662–667. doi:10.1097/FBP.0b013e328331ba1b. PMID 19741506. 
  4. ^ Roberta Bursi; Gul Erdemli; Robert Campbell; Matthew M. Hutmacher; Thomas Kerbusch; David Spanswick; Ross Jeggo; Kari R. Nations; Peter Dogterom; Jacques Schipper; Mohammed Shahid (December 2011). "Translational PK–PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576". Psychopharmacology. 218 (4): 713–724. doi:10.1007/s00213-011-2365-6. PMID 21647578. 
  5. ^ Kent Jardemark; Monica M. Marcus; Anna Malmerfelt; Mohammed Shahid; Torgny H. Svensson (May 2012). "Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission". Psychopharmacology. 221 (2): 115–131. doi:10.1007/s00213-011-2554-3. PMID 22068461. 
  6. ^ Fabio Fumagalli; Francesca Calabrese; Alessia Luoni; Mohammed Shahid; Giorgio Racagni; Marco A. Riva (February 2012). "The AMPA receptor potentiator Org 26576 modulates stress-induced transcription of BDNF isoforms in rat hippocampus". Pharmacological Research. 65 (2): 176–181. doi:10.1016/j.phrs.2011.10.004. PMID 22079295. 
  7. ^ Machado-Vieira, R; Henter, ID; Zarate CA, Jr (May 2017). "New targets for rapid antidepressant action". Progress in neurobiology. 152: 21–37. doi:10.1016/j.pneurobio.2015.12.001. PMC 4919246Freely accessible. PMID 26724279. 



Retrieved from "https://en.wikipedia.org/w/index.php?title=ORG-26576&oldid=829585159"
This content was retrieved from Wikipedia : http://en.wikipedia.org/wiki/ORG-26576
This page is based on the copyrighted Wikipedia article "ORG-26576"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA